NASDAQ:MGX Metagenomi (MGX) Stock Price, News & Analysis $1.30 -0.03 (-1.89%) As of 02:49 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock About Metagenomi Stock (NASDAQ:MGX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Metagenomi alerts:Sign Up Key Stats Today's Range$1.28▼$1.3550-Day Range$1.14▼$1.4852-Week Range$1.13▼$3.95Volume173,236 shsAverage Volume214,760 shsMarket Capitalization$48.76 millionP/E RatioN/ADividend YieldN/APrice Target$7.00Consensus RatingModerate Buy Company Overview Metagenomi, Inc. (NASDAQ: MGX) is a biotechnology company that specializes in the discovery and engineering of novel proteins and enzymes using metagenomics and CRISPR-based genome editing. The company’s proprietary platform integrates vast environmental DNA libraries with advanced machine learning and high-throughput screening to identify, optimize and commercialize enzymes for industrial, agricultural and pharmaceutical applications. By tapping into genetic diversity found in nature, Metagenomi aims to accelerate the development of tailored biocatalysts that improve process efficiency, reduce costs and support sustainability initiatives. Metagenomi’s technology offerings include custom enzyme discovery services, protein engineering tools and licensing of optimized biocatalysts to partners across multiple sectors. The company works with manufacturers to enhance biofuel production, create greener chemical intermediates and develop more effective formulations for detergents, textiles and crop protection. In the biopharmaceutical realm, Metagenomi’s novel genome-editing components have the potential to drive next-generation gene therapies and precision medicine approaches by enabling targeted modifications in living cells. Founded in 2019 and headquartered in South San Francisco, Metagenomi has rapidly expanded through strategic collaborations and research partnerships with industry leaders and academic institutions. The company’s management team combines deep expertise in genomics, computational biology and industrial biotechnology, positioning Metagenomi to serve global markets and address growing demand for sustainable, biologically derived solutions. As it advances its pipeline programs and broadens its partner network, Metagenomi continues to pursue breakthrough innovations that bridge metagenomics data with real-world manufacturing needs.AI Generated. May Contain Errors. Read More Metagenomi Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks63rd Percentile Overall ScoreMGX MarketRank™: Metagenomi scored higher than 63% of companies evaluated by MarketBeat, and ranked 249th out of 848 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingModerate Buy Consensus RatingMetagenomi has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 1 strong buy rating, 3 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialMetagenomi has a consensus price target of $7.00, representing about 440.5% upside from its current price of $1.30.Amount of Analyst CoverageMetagenomi has only been the subject of 3 research reports in the past 90 days.Read more about Metagenomi's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Metagenomi are expected to grow in the coming year, from ($2.13) to ($1.66) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Metagenomi is -0.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Metagenomi is -0.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMetagenomi has a P/B Ratio of 0.31. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Metagenomi's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.33% of the float of Metagenomi has been sold short.Short Interest Ratio / Days to CoverMetagenomi has a short interest ratio ("days to cover") of 11.43, which indicates bearish sentiment.Change versus previous monthShort interest in Metagenomi has recently decreased by 4.12%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMetagenomi does not currently pay a dividend.Dividend GrowthMetagenomi does not have a long track record of dividend growth. News and Social Media2.6 / 5News Sentiment0.19 News SentimentMetagenomi has a news sentiment score of 0.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Metagenomi this week, compared to 1 article on an average week.Search Interest9 people have searched for MGX on MarketBeat in the last 30 days. This is an increase of 125% compared to the previous 30 days. Company Ownership1.2 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Metagenomi insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,749.00 in company stock.Percentage Held by Insiders12.50% of the stock of Metagenomi is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsMetagenomi has minimal institutional ownership at this time.Read more about Metagenomi's insider trading history. Receive MGX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Metagenomi and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MGX Stock News HeadlinesMetagenomi (NASDAQ:MGX) Price Target Cut to $5.00 by Analysts at Chardan CapitalJuly 7 at 8:42 AM | americanbankingnews.comMetagenomi, Inc. (NASDAQ:MGX) Given Average Rating of "Moderate Buy" by BrokeragesJune 28, 2026 | americanbankingnews.comIs the fix for AI's runaway power problem your golden ticket?The government just committed $200 billion to building computer chips on American soil - one of the largest technology bets in U.S. history. George Gilder, who has tracked technology signals for over 40 years, believes Washington just tipped its hand. He says this move points to a coming shift in computing that could leave today's machines behind - and most investors have already moved past the headline.July 8 at 1:00 AM | Eagle Publishing (Ad)Metagenomi Announces Board Changes and Shareholder Meeting ResultsJune 10, 2026 | tipranks.comDid Metagenomi Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?June 5, 2026 | prnewswire.comMetagenomi Therapeutics, Inc. to Present at the Jefferies Global Healthcare ConferenceMay 28, 2026 | globenewswire.comMetagenomi Therapeutics (MGX) price target decreased by 10.71% to 8.50May 14, 2026 | msn.comMetagenomi Therapeutics, Inc. (NASDAQ:MGX) Just Reported And Analysts Have Been Cutting Their EstimatesMay 14, 2026 | finance.yahoo.comSee More Headlines MGX Stock Analysis - Frequently Asked Questions How have MGX shares performed this year? Metagenomi's stock was trading at $1.62 on January 1st, 2026. Since then, MGX shares have decreased by 20.1% and is now trading at $1.2950. How were Metagenomi's earnings last quarter? Metagenomi, Inc. (NASDAQ:MGX) announced its quarterly earnings data on Monday, May, 11th. The company reported ($0.61) earnings per share for the quarter, missing analysts' consensus estimates of ($0.60) by $0.01. The company had revenue of $1.25 million for the quarter, compared to analyst estimates of $5.90 million. Metagenomi had a negative trailing twelve-month return on equity of 51.23% and a negative net margin of 384.61%. When did Metagenomi IPO? Metagenomi (MGX) raised $100 million in an IPO on Friday, February 9th 2024. The company issued 6,250,000 shares at $15.00-$17.00 per share. How do I buy shares of Metagenomi? Shares of MGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Metagenomi own? Based on aggregate information from My MarketBeat watchlists, some other companies that Metagenomi investors own include Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Home Depot (HD). Company Calendar Last Earnings5/11/2026Today7/08/2026Next Earnings (Estimated)8/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (7m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 MGX's financial health is in the Yellow zone, according to TradeSmith. MGX has been in this zone for over 7 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MGX Previous SymbolNASDAQ:MGX CIK1785279 Webwww.metagenomi.co Phone510-871-4880FaxN/AEmployees236Year Founded2018Price Target and Rating Average Price Target for Metagenomi$7.00 High Price Target$9.00 Low Price Target$5.00 Potential Upside/Downside+440.5%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($2.30) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$87.87 million Net Margins-384.61% Pretax Margin-385.27% Return on Equity-51.23% Return on Assets-36.62% Debt Debt-to-Equity RatioN/A Current Ratio6.43 Quick Ratio6.43 Sales & Book Value Annual Sales$25.21 million Price / Sales1.93 Cash FlowN/A Price / Cash FlowN/A Book Value$4.22 per share Price / Book0.31Miscellaneous Outstanding Shares37,650,000Free Float32,941,000Market Cap$48.76 million OptionableN/A Beta0.69 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:MGX) was last updated on 7/8/2026 by MarketBeat.com Staff. From Our PartnersSMX: From Under-the-Radar to Must-Watch!SMX (Security Matters) PLC embeds molecular-level markers directly into materials - plastics, metals, fuels, a...Smallcaps Daily | SponsoredIs the fix for AI's runaway power problem your golden ticket?The government just committed $200 billion to building computer chips on American soil - one of the largest te...Eagle Publishing | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredSolar is dead. Here’s what replaces it.Starting July 4th, every new solar and wind project in America loses its federal tax credits. But one zero-car...Behind the Markets | SponsoredThey told you not to miss this oneThe largest companies in the SP 500 are now more overvalued relative to fundamentals than they were at the abs...Thor Metals | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredThe window is closingWe printed 1,000 copies of this report and 688 are gone—when the last one goes out, we're pulling it offline b...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Metagenomi, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Metagenomi With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
